There Is No Shortcut to Phase 3: Why Dose Justification in Phase 2 Is the Most Underinvested Decision in Drug Development

Selecting the right dose is one of the most important decisions before pivotal development begins. This guide explains how model-informed drug development (MIDD), clinical pharmacology, and pharmacometrics can help sponsors build a more defensible dose rationale before major time, capital, and regulatory risk are on the line.

What you will take away from this guide:

• An executive-level understanding of MIDD, ICH M15, and their role in modern regulatory decision-making.
• A clear view of Phase 2 decisions that most often increase dose-selection risk.
• A Best Practice framework for assessing whether a program is Phase 3-ready.
• A real-world case study showing how integrated CP strategy can preserve development flexibility.

Every FDA interaction is high-stakes. The right preparation turns a meeting request into a regulatory win.

In this guide, you’ll learn how to:

• Map key PDUFA timelines so your team hits every meeting request and package deadline
• Build a briefing strategy that gets clear, actionable responses — not vague feedback
• Apply a framework built from real-world experience supporting global regulatory programs